$KERX Recent News Nasdaq extends break to less-charted

New Post Public Reply Private Reply Replies (0) Message Board

Dec 6, 2013 at 12:52 PM

$KERX Recent News

Nasdaq extends break to less-charted territory 11:42 a.m. Dec. 2, 2013 - Michael Ashbaugh
6 movers to watch 2:08 p.m. Nov. 6, 2013 - The Trading Deck
Keryx climbs after treatment shows positive result 10:01 a.m. Nov. 5, 2013 - MarketWatch.com
Six stocks to watch for some upside 2:21 p.m. April 11, 2013 - The Trading Deck
6 gut checks before the stock market's opening bell 6:47 a.m. March 7, 2013 - Shawn Langlois
Towerstream, Vanguard and others price offerings 10:32 a.m. Jan. 31, 2013 - MarketWatch.com
6 gut checks before the stock market's opening bell 6:52 a.m. Jan. 31, 2013 - Shawn Langlois
Keryx Biopharmaceuticals up 8.5% in premarket 7:58 a.m. Jan. 29, 2013 - Steve Gelsi
Monday’s movers: Herbalife clobbered on FTC news 4:30 p.m. Jan. 28, 2013 - Sue Chang
In focus: No letup by the bulls 7:45 p.m. Jan. 23, 2013 - Lawrence G. McMillan
Keryx Biopharma rises 17% in premarket trades 7:36 a.m. Jan. 23, 2013 - Steve Gelsi
Monday’s biggest gaining and declining stocks 3:37 p.m. April 23, 2012 - MarketWatch
Monday’s biggest gaining & declining stocks 4:56 p.m. April 2, 2012 - Kate Gibson
Keryx, AEterna implode on failed drug study 10:13 a.m. April 2, 2012 - Val Brickates Kennedy
Keryx, AEterna rally ahead of study results 12:34 p.m. March 16, 2012 - Val Brickates Kennedy
Keryx , AEterna rally ahead of study results 12:32 p.m. March 16, 2012 - Val Brickates Kennedy
Top longs and shorts to watch 12:18 p.m. March 6, 2012 - The Trading Deck
AEterna, Keryx soar on study speculation 12:52 p.m. March 5, 2012 - Val Brickates Kennedy
Keryx Biopharmaceuticals Inc. shares gain 9.6% 9:35 a.m. Nov. 30, 2010 - Kate Gibson
Powerful uptrend meets major resistance 9:28 a.m. Oct. 25, 2010 - Michael Ashbaugh

Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma 6:00 a.m. Today - TheStreet.com
Zerenex- The New Spark For Keryx? 7:42 a.m. Nov. 25, 2013 - Seeking Alpha
Commit To Buy Keryx Biopharmaceuticals At $8, Earn 28.1% Using Options 1:29 p.m. Nov. 19, 2013 - TheStreet.com
Why Doctors, Dialysis Providers And Investors Are Excited About Zerenex 10:12 a.m. Nov. 11, 2013 - Seeking Alpha
Key Issues Surrounding The Zalicus Catalyst Trade 8:56 a.m. Nov. 8, 2013 - Seeking Alpha
Keryx Biopharma Issues Update from Ongoing Zerenex LT Safety Extension Study 7:33 a.m. Nov. 8, 2013 - benzinga.com
Keryx Should Continue To Climb 5:04 a.m. Nov. 8, 2013 - Seeking Alpha
Biotech Stock Mailbag: Galectin, Keryx, Navidea, Cytori 6:10 p.m. Nov. 7, 2013 - TheStreet.com
Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX) 10:29 a.m. Nov. 7, 2013 - TheStreet.com
UPDATE: J.P. Morgan Reiterates on Keryx Biopharmaceuticals on Model Update After Positive NDD-CKD Data 9:12 a.m. Nov. 7, 2013 - benzinga.com
Keryx Biopharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript 1:48 a.m. Nov. 6, 2013 - Seeking Alpha
Data Support Keryx's Anemia Drug In A New And Large Market 1:43 p.m. Nov. 5, 2013 - Seeking Alpha
Four Big Healthy Biotech Gainers, One Big Loser 1:07 p.m. Nov. 5, 2013 - 247WallSt.com
Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study 6:36 a.m. Nov. 5, 2013 - benzinga.com
10-Q: KERYX BIOPHARMACEUTICALS INC 5:05 p.m. Nov. 4, 2013 - Edgar Online - (EDG = 10Q, 10K)
UPDATE: JMP Securities Reiterates on Keryx Biopharmaceuticals on Blockbuster Potential Growing for Zerenex 8:17 a.m. Nov. 4, 2013 - benzinga.com
A Look Back At Biotech Short Picks 2:18 p.m. Oct. 31, 2013 - Seeking Alpha
4 Biotech Stocks Making Headlines 10:25 a.m. Oct. 28, 2013 - Wall St. Cheat Sheet
Sunshine Heart's Pulse System Could Revolutionize How Heart Failure Is Treated 8:59 a.m. Oct. 21, 2013 - Seeking Alpha
Trade-Ideas: Keryx Biopharmaceuticals (KERX) Is Today's "Perilous Reversal" Stock 10:44 a.m. Oct. 18, 2013 - TheStreet.com

Stock Initiation of the Day: Keryx Biopharma, GlaxoSmithKline, AstraZeneca, and Raptor Pharma 10:48 a.m. Today - PR Newswire
Regulatory Approval, Requisite Consents and Expiration of Consent Solicitations, and Stock Price Movements - Research Report on Thermo Fisher, Endo, Perrigo, Keryx, and Waters 8:00 a.m. Dec. 4, 2013 - PR Newswire
Bullish Trend Analysis: Tesla Motors Inc, XOMA Corp, Keryx Biopharmaceuticals, Oncomed Pharmaceuticals 9:01 a.m. Dec. 3, 2013 - ACCESSWIRE
Grants and Stock Movements of Major Drug Manufacturers - Research Report on AbbVie, Keryx Biopharmaceuticals, Pacira Pharmaceuticals, Rockwell Medical, and Impax Laboratories 8:00 a.m. Nov. 22, 2013 - PR Newswire
Extension Study Data, Financial Results, Scheduled Conferences and Presentations - Research Report on Keryx, Raptor, Pacira, Horizon Pharma, and Impax 8:00 a.m. Nov. 13, 2013 - PR Newswire
Morning Research: GlaxoSmithKline PLC, Keryx Biopharma Inc., AstraZeneca PLC, and Raptor Pharma Corp. 8:00 a.m. Nov. 11, 2013 - PR Newswire
IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals 8:46 a.m. Nov. 8, 2013 - PR Newswire
Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis 8:30 a.m. Nov. 8, 2013 - GlobeNewswire
Legal Settlements, Stock Price Updates, Financial Results, and Commencement of Clinical Studies - Research Report on Johnson & Johnson, Elan, Tenet, Opko and Keryx Biopharmaceuticals 8:00 a.m. Nov. 7, 2013 - PR Newswire
M&A, Earnings and News Round Up: Keryx Biopharmaceuticals, Pandora Media, Marvell Technology Group, Starbucks, Cell Therapeutics 8:46 a.m. Nov. 6, 2013 - PR Newswire
Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus and Iron Deficiency Anemia 5:00 p.m. Nov. 4, 2013 - GlobeNewswire
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results 4:30 p.m. Nov. 4, 2013 - GlobeNewswire
Quarterly Reports, License Applications, and Abstract Presentations - Research on Elan, NPS, ICON, Keryx, and Healthways 9:00 a.m. Oct. 29, 2013 - PR Newswire
Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex(TM) New Drug Application 8:30 a.m. Oct. 21, 2013 - GlobeNewswire
Financial Results, Quarterly Earnings Schedules, Marketing Authorizations, Completed Acquisitions, and New Drug Applications - Research Report on Johnson & Johnson, AbbVie, GSK, AstraZeneca, and Keryx 8:00 a.m. Oct. 18, 2013 - PR Newswire
Technical Study: AstraZeneca PLC, GlaxoSmithKline PLC, Keryx Biopharma Inc., and Raptor Pharma Corp. 12:51 p.m. Oct. 17, 2013 - PR Newswire
Critical Alerts For Goldman Sachs, Netflix, Nasdaq, Aetna, and Keryx Biopharmaceuticals Released By InvestorsObserver 9:31 a.m. Oct. 17, 2013 - PR Newswire
Keryx Biopharmaceuticals' Zerenex(TM) (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013 8:31 a.m. Oct. 17, 2013 - GlobeNewswire
Drug Approvals, Data Presentations, Clinical Trials, New Appointments, and Corporate Events - Research Report on Johnson & Johnson, Novo Nordisk, Isis, Keryx, and The Medicines Company 8:00 a.m. Oct. 9, 2013 - PR Newswire
Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex(TM) New Drug Application 8:30 a.m. Oct. 8, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Xerox Faces Probes After $130M Profit Forecast Slash

When the Trust Breaks October 29, 2026 was a gut punch for Xerox investors. Watching the outlook dive by $130 million, the coffee-feeling in the trading rooms turned into something more bitter. A $105 million boost they once celebrated from tariff receivables now seems to be a fleeting shadow, as Xerox itself scuttles its adjusted operating income for 2026 to a range of...

ATTACK SHARK's X60: A New Era in Gaming Audio

Gaming Audio Gets a Power Boost with X60 We're diving headfirst into an era where gaming headsets promise more bells and whistles than ever before. This isn't just some random gadget plopped on the market. ATTACK SHARK's X60 Gaming Headset is strutting in, guns blazing, ready to take on the heavyweights in the competitive gaming world. It's not just about being another...

DAR Logs Massive 587,000 Service Hours Nationwide

A Month of Patriotism and Service You've got to hand it to the Daughters of the American Revolution (DAR)—when they commit, they go all in. This year, they turned their usual Day of Service into a full-blown Month of Service, packing in over 587,000 hours of volunteering nationwide. From historic spots to food pantries, DAR members showed up, and honestly, it's the kind...

Wabi's $1.25B Valuation: A New Era for AI?

By Logan Wright Updated Oct 29, 2026 Category News Views 171

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...

CopperWood Senior Living Revives Historic Campus

A Fresh Start for Peapack-Gladstone's Corporate Relic Dust off the pages of history—Peapack-Gladstone's old Pfizer/Beneficial Finance campus is getting a makeover, and boy, it’s not your run-of-the-mill renovation. We're talking adaptive reuse to the tune of nearly $200 million, morphing this architectural gem into CopperWood Senior Living. With all the office...

Pozdeutinurad Phase 3 Success Impact on Sobi and Market

Pozdeutinurad's Phase 3 Triumph Ah, the life of biotech—constant ups and downs, but when you hit a homerun, it feels like the market stands still for a second. Pozdeutinurad's recent Phase 3 REDUCE-2 study results are one of those moments for Swedish Orphan Biovitrum AB, or Sobi for short. This study showed some seriously compelling data: clinically meaningful and...

David Cornue Brings Story Insights to SXSW 2027

Crafting Stories with Precision: Cornue's Return In the world where Austin becomes a melting pot of ideas every spring, the return of David Cornue to SXSW casts a familiar, yet electrifying spark. This best-selling author and television whiz is slated to share his story magic at two workshops: one in the Lifestyle track and the other in the Film & TV track. Folks on-site...

LanguageLine AI App Earns Vizient Technology Kudos

Tech Talk: LanguageLine's AI App Gains Important Recognition Diving headfirst into the chaotic world of healthcare, LanguageLine's AI Translation App earned a standout accolade. Just announced, it's snagged the Innovative Technology Designation from Vizient, the heavyweight champ in healthcare performance improvement. On the scene since the end of October, they rolled the...

Ashling's New Feat: Microsoft Recognition in AI

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

Maison Martell Bridging Artistry: Davido Meets Prince Gyasi

Maison Martell Dances to a New Beat The world's oldest cognac house, Maison Martell, is mixing things up in a way that’ll make your typical whiskey-on-the-rocks seem like child’s play. They've snagged Afrobeat heavyweight Davido and renowned visual poet Prince Gyasi to spin a fresh narrative, one where melody and imagery play in harmony. While this ain't your usual...